Senseonics, the makes of the Eversense 365 implantable CGM, has begun the first in-human clinical study of Freedom, an investigational implantable continuous glucose monitor (CGM) designed to work without an external transmitter. The system builds on the technology used in Eversense 365, adding an integrated battery and Bluetooth communication to the implanted sensor. This would allow glucose readings to be sent to a smartphone app without requiring a separate transmitter worn on the skin.

Following preclinical results in Q2 2026, the company has chosen a preferred Bluetooth Low Energy (BLE) antenna design and implantation approach for its first-in-human study. Over approximately seven weeks and 18,500+ communication data points, the design achieved 100% communication success within the target distance. These findings support advancing the technology to human evaluation.

This first-in-human feasibility study will evaluate safety and device functionality, with Senseonics planning to begin a pivotal study in 2027 and targeting a potential commercial launch in 2028.

Currently, Senseonics offers Eversense 365, an implantable CGM designed to last up to a year. A healthcare provider inserts the small sensor under the skin of the upper arm, where it measures glucose continuously. However, users must wear a removable external transmitter over the implant site to send readings to their phone. Eversense 365 is currently compatible to automate insulin with the twiist AID System and soon, the iLet insulin pump. We recently spoke with an expert about his experience using Eversense 365 and learned more about his experience from insertion to day-to-day maintenance.

Freedom is not Senseonics’ only next-generation CGM in development. The company is also developing Gemini, an implantable sensor with an integrated battery that could offer users flexibility when it comes to transmitter usage. In scan-only mode, users would scan the sensor with a smartphone to retrieve stored glucose data (up to 8 hours), while continuous monitoring would remain available only when the wearable transmitter is worn. A flexible mode would allow users to switch between the two approaches. While Gemini aims to give users more flexibility in how they access glucose data, Freedom takes the concept further by integrating Bluetooth into the implant itself for continuous, automatic readings without an on-body transmitter. For those who use AID systems, Freedom seems to be the correct option of the two.

What do you think about a fully implantable CGM with no external hardware? Let us know in the comments! Would you get it?